An open-label, balanced, randomized, single oral dose, two-stage, three-treatment, six-sequence, four period, crossover comparative bioavailability study of Teriparatide 4 mg Capsule (T1 and T2) with Teriparatide 20 mcg Subcutaneous injection among healthy, adult male and/or post-menopausal females under fasting and fed conditions.

Erode Cancer centre0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•1)Study participant who is able to provide written informed consent.
•2)Study participant is a healthy adult human male (age 18 - 45 years) or healthy Post menopausal female (age 40-60 years).
•3)Study participant Body Mass Index of 18.5 kg/m2 and 24.9 kg/m2 with body weight at least 55 kg for men and at least 48 kg for women.
•4)Study participant with baseline systolic blood pressure with upper limit of less than 140 mmHg and lower limit of more than or equal to 100 mm Hg. Similarly baseline diastolic blood pressure with upper limit less than 90 mm Hg and lower limit more than or equal to 60 mmHg.
•5)Study participant with heart rate not less than 60 beats/min and not more than 100 beats/min and respiratory rate not less than 14/min and not more than 18/min.
•6)Study participant has normal health as determined by medical history and physical examination performed within 21 days prior to the dosing of period 1.
•7)Study participant with normal ECG, chest X-ray and vital signs.
•8)Availability of a study participant for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
•9)Study participant is postmenopausal with spontaneous amenorrhea for at least 01 year.
•Study participant with surgical menopause (who has undergone hysterectomy at least 01 year back).

排除标准

•1)Study participant who is incapable of understanding the informed consent.
•2)Study participant with history of hypersensitivity or idiosyncratic reaction to active or inactive ingredient in the Teriparatide or any other related drug or to milk, eggs or chicken.
•3)Study participant with any evidence of impairment of renal, hepatic, cardiac, pulmonary or gastrointestinal function. Study volunteers with a history of tuberculosis, epilepsy, asthma (during past 05 years), diabetes, psychosis, eye disorders will not be eligible for the study.
•4)Study participant who regularly smokes more than 10 cigarettes daily or has difficulty in abstaining from tobacco for the duration of each study period.
•5)Study participant who are currently on any medications or supplements known to cause systemic hypotension.
•6)Study participant who has taken over the counter or prescribed medications, including any enzyme modifying drugs (known to induce or inhibit hepatic enzyme activity) or any systemic medication within the past 30 days prior to dosing in first period.
•7)Study participant who has taken any over the counter medicinal products, herbal medications within 07 days prior to study check-in and throughout the study and any prescription medications within 14 days prior to study check-in and throughout the study
•8)Study participant who received previous treatment with: bisphosphonates, hormonal (estrogen/progestogen) replacement therapy (HRT), tibolone, raloxifene, calcitonin, within 6 months prior to randomization; systemic corticosteroid use >2 weeks of >5 mg prednisone or equivalent/average day within the past 3 months prior to randomization; anabolic androgens within six months prior to randomization; any prior use of PTH for more than 1 week; strontium ranelate at any time prior to screening;
•9)Study participant with Hypercalcemia, serum calcium >10.2 mg/dL; Vitamin D 25-(OH) serum levels of less than12 ng/mL.
•10)Study participant with history of cardiovascular signs, symptoms, conditions, or diseases.
•11)Study participant with history of any psychiatric illness, which may impair the ability to provide written, informed consent.
•12)Study participant with history of alcohol or substance abuse within the last 05 years.
•13)Study participant with clinically significant abnormal values of laboratory parameters.
•14)Study participant had participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 03 months.
•15)Study participant who is unable to or unlikely to be compliant with protocol requirements or restrictions.
•16)Study drug is contraindicated for medical reasons.
•17)Study participant who is intolerant to venipuncture.
•18)Female volunteer who has used implanted or injected hormonal contraceptives anytime during the 06 months prior to study or used oral contraceptives within 14 days before dosing.
•19)Female volunteer who demonstrates a positive pregnancy test.
•Each female study volunteer will be screened for pregnancy at screening and at check-in before each study period. Study volunteer with a positive or inconclusive result will be withdrawn from the study.

研究者

发起方

Erode Cancer centre

相似试验

已完成

不适用

Two Period Crossover study comparison of Narpega oral liquid of KMS health center and LovazaÂ® of glaxosmithkline with 1 Quercetin capsule of KMS in healthy adult human subject under fasting conditions.

CTRI/2022/08/044582KMS Health center pvt ltd

尚未招募

不适用

Aminocaproic acid Tablets 1000 mg BE Fed Study

CTRI/2019/05/018932Optimus Pharma Pvt Ltd

已完成

1 期

Comaparing the two different treatments of Darunavir and Ritonavir Tablet 800 mg/100 mg of Emcure Pharmaceuticals Ltd., India with DANAVIR R (Darunavir & Ritonavir Tablet 800 mg/100 mg) of Hetero Healthcare Limited, India in healthy, adult, human subjects under fed conditions

CTRI/2020/09/027593Emcure Pharmaceuticals Limited28

已完成

1 期

A clinical trial study to determine the bioavailability of different formulations of curcumin tablets.

CTRI/2021/06/034356KMS Health Center Pvt Ltd

尚未招募

Unknown

Bioequivalence study of Propiomazine Tablets 25 mg in healthy, adult, human Subjects under fasting conditions.

CTRI/2024/04/066196Centaur Pharmaceuticals Pvt. Ltd